Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene [1]

Leukemia

Volumn 18, Issue 5, 2004, Pages 1020-1021

  Janssen, J J W M ^a   Hochhaus, A ^b   van Oostveen, J W ^a   Waisfisz, Q ^a   Schuurhuis, G J ^a   Ossenkoppele, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARAGINASE; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; BONE MARROW; CASE REPORT; CHROMOSOME ANALYSIS; DOSE RESPONSE; DRUG WITHDRAWAL; FUSION GENE; HUMAN; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; GENETICS;

ADULT; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; PIPERAZINES; POLYMERASE CHAIN REACTION; PYRIMIDINES; RNA, MESSENGER;

EID: 2342647429     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403338     Document Type: Letter

References (8)

1. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
2. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
3. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002; 417: 664-667.
4. Nakamura T, Aoki S, Kitajima K, Takahashi T, Matsumoto K, Nakamura T. Molecular cloning and characterization of Kremen, a novel kringle-containing transmembrane protein. Biochim Biophys Acta 2001; 1518: 63-72.
5. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461-463.
6. Müller MC, Gattermann N, Lahaye T, Deininger MW Berndt A, Fruehauf S et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003; 17: 2392-2400.
7. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114-119.
8. Huntly BJ, Guilhot F, Reid AG, Vassiliou C, Hennig E, Franke C et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205-2212.